68 Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients
Journal of Nuclear Medicine · 2024-06 · 65 (6) · 856-863
DOI: 10.2967/jnumed.123.267110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 11.04.2024. Verfasst von Changsong Qi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Early Drug Development, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of …. Hauptthemen laut MEDLINE: Claudins, Gastrointestinal Neoplasms, Gallium Radioisotopes, Whole Body Imaging. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
68Ga-labeled nanobody (68Ga-NC-BCH) is a single-domain antibody-based PET imaging agent. We conducted a first-in-humans study of 68Ga-NC-BCH for PET to determine its in vivo biodistribution, metabolism, radiation dosimetry, safety, and potential for quantifying claudin-18 isoform 2 (CLDN18.2) expression in gastrointestinal cancer patients.
Methods
Initially, we synthesized the probe 68Ga-NC-BCH and performed preclinical evaluations on human gastric adenocarcinoma cell lines and xenograft mouse models. Next, we performed a translational study with a pilot cohort of patients with advanced gastrointestinal cancer on a total-body PET/CT scanner. Radiopharmaceutical biodistribution, radiation dosimetry, and the relationship between tumor uptake and CLDN18.2 expression were evaluated.
Results
68Ga-NC-BCH was stably prepared and demonstrated good radiochemical properties. According to preclinical evaluation,68Ga-NC-BCH exhibited rapid blood clearance, high affinity for CLDN18.2, and high specific uptake in CLDN18.2-positive cells and xenograft mouse models. 68Ga-NC-BCH displayed high uptake in the stomach and kidney and slight uptake in the pancreas. Compared with 18F-FDG, 68Ga-NC-BCH showed significant differences in uptake in lesions with different levels of CLDN18.2 expression.
Conclusion
A clear correlation was detected between PET SUV and CLDN18.2 expression, suggesting that 68Ga-NC-BCH PET could be used as a companion diagnostic tool for optimizing treatments that target CLDN18.2 in tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Early Drug Development, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Ho…
- Department of Nuclear Medicine, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), State Key Laboratory of Holistic Integrative Management of Gastrointest…
- Medical Isotopes Research Center, Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing, China; and.
- Chengdu AlpVHHs Co. Ltd., Chengdou, China.
Zitieren
APA
Qi, C., Guo, R., Chen, Y., Li, C., Liu, C., Zhang, M., Zhang, C., Zhang, X., Hou, X., Chen, B., Jia, B., Yang, Z., Shen, L., & Zhu, H. (2024). 68 Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients. Journal of Nuclear Medicine, 65(6), 856-863. https://doi.org/10.2967/jnumed.123.267110
Vancouver
Qi C, Guo R, Chen Y, Li C, Liu C, Zhang M, et al. 68 Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients. Journal of Nuclear Medicine. 2024;65(6):856-863. doi:10.2967/jnumed.123.267110
BibTeX
@article{Qi2024,
author = {Qi, Changsong and Guo, Rui and Chen, Yan and Li, Chenzhen and Liu, Chang and Zhang, Miao and Zhang, Cheng and Zhang, Xiaotian and Hou, Xingguo and Chen, Bo and Jia, Bing and Yang, Zhi and Shen, Lin and Zhu, Hua},
title = {68 Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients},
journal = {Journal of Nuclear Medicine},
year = {2024},
volume = {65},
number = {6},
pages = {856--863},
doi = {10.2967/jnumed.123.267110}
}
EUVIMED